首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1535835

偏頭痛藥物市場 - 按藥物類別（止痛藥 [曲普坦、鎮痛藥]、預防藥 [抗驚厥藥、抗憂鬱藥]）、給藥途徑（口服、注射）、類型（處方藥、非處方藥）、配銷通路- 全球預測（2024 年 - 2032 年）

Migraine Drugs Market - By Drug Class (Pain Relieving [Triptan, Analgesic], Preventive [Anticonvulsant, Antidepressant]), Route of Administration (Oral, Injectable), Type (Prescription, OTC), Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年06月18日 | 出版商:

Global Market Insights Inc. | 英文 132 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於人們對改善診斷的認知不斷增強以及藥物開發的進步，預計 2024 年至 2032 年全球偏頭痛藥物市場規模的複合年成長率將達到 6.7%。

最近，有些人正在尋求醫療護理並獲得準確的診斷，導致對有效治療的需求更大。同時，研究人員正在透過結合藥理學和技術的進步來開發新的偏頭痛藥物，以增強治療選擇。這些創新正在提高藥物療效，同時減少副作用並提供更有針對性的治療。例如，2024 年 1 月，Akums 推出了 Lasmiditan 片劑，用於緩解偏頭痛症狀，以增強治療選擇，從而提供有針對性的方法來管理偏頭痛並透過先進的治療效果改善患者的治療效果。

偏頭痛藥物市場按藥物類別、給藥途徑、類型、配銷通路和地區分類。

按藥物類別分類，由於強烈要求在偏頭痛發作之前降低偏頭痛發作的頻率和嚴重程度，預計預防性藥物領域從 2024 年到 2032 年將以顯著的複合年成長率成長。預防性藥物的開發和處方是為了控制慢性偏頭痛並預防使人衰弱的發作。它們的工作原理是針對引發偏頭痛的潛在機制，從而減少攻擊的總體發生率和影響。此外，正在進行的研究和技術進步正在完善預防性治療，為慢性偏頭痛患者提供更有效和量身定做的選擇。

由於為患者提供更大便利和可及性的需求日益成長，在線藥房配銷通路領域的偏頭痛藥物行業價值預計將在 2024 年至 2032 年期間擴大。這些平台提供一系列偏頭痛藥物，包括處方藥和非處方藥，進一步允許使用者在家中輕鬆訂購和接受治療。線上藥局的日益普及也使個人能夠更輕鬆地及時獲取藥物並更有效地管理他們的治療計劃。

從地區來看，由於醫療保健支出的增加以及對偏頭痛疾病的認知和診斷的提高，預計歐洲偏頭痛藥物行業規模將在 2024 年至 2032 年間激增。公司正在投資先進的治療方法來支持偏頭痛患者。同時，意識的提高和更好的診斷實踐正在導致該地區更準確的診斷和對有效偏頭痛治療的更大需求。

產業生態系統分析
產業影響力
- 成長動力
  - 偏頭痛的發生率和盛行率不斷增加
  - 患者對非侵入性治療的偏好不斷上升
  - 提高對偏頭痛的認知和診斷
- 產業陷阱與挑戰
  - 嚴格的監管要求
  - 來自替代療法的競爭
成長潛力分析
監管環境
管道分析
定價分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀錶板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

主要趨勢
止痛藥
- 曲普坦類
- 止痛藥
- 迪坦斯
- 其他止痛藥物
處方藥
- 抗驚厥藥
- 抗憂鬱藥
- 乙種腎上腺阻斷劑
- CGRP抑制劑
- 其他預防藥物

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
口服
可注射
鼻腔
經皮

第 7 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
處方藥
非處方藥

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
藥局和零售藥局
網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Amgen, Inc.
Astellas Pharma
AstraZeneca Plc
Azurity Pharmaceutical, Inc.
Dr. Reddy's Laboratories, Inc.
Eli Lilly and Company
Endo Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Lannett Company, Inc.
Lundbeck A/S
Pfizer, Inc.
Sanofi SA
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited

簡介目錄

Product Code: 9899

Global Migraine Drugs Market size is anticipated to witness 6.7% CAGR from 2024 to 2032, due to the increasing awareness for improved diagnosis alongside advancements in drug development.

Lately, several individuals are seeking medical attention and receiving accurate diagnoses, leading to greater demand for effective treatments. Concurrently, researchers are developing new migraine drugs by incorporating advancements in pharmacology and technology to enhance treatment options. These innovations are improving drug efficacy while reducing side effects and providing more targeted therapies. For instance, in January 2024, Akums launched the Lasmiditan tablet to alleviate migraine symptoms to enhance treatment options for providing a targeted approach to managing migraines and improving patient outcomes with advanced therapeutic benefits.

The migraine drugs market is segregated into drug class, route of administration, type, distribution channel, and region.

By drug class, the preventive medication segment is estimated to rise at a significant CAGR from 2024 to 2032 due to the strong requirement to reduce the frequency and severity of migraine attacks before they occur. Preventive medications are developed and prescribed to manage chronic migraines and prevent debilitating episodes. They work by targeting underlying mechanisms that trigger migraines, thereby decreasing the overall occurrence and impact of attacks. Additionally, the ongoing research and technological advancements are refining preventive treatments for more effective and tailored options for individuals with chronic migraines.

Migraine drugs industry value from the online pharmacies distribution channel segment is expected to expand from 2024 to 2032, fueled by the increasing need for offering greater convenience and accessibility for patients. These platforms are providing a range of migraine medications, including both prescription and over-the-counter options, further allowing users to easily order and receive their treatments from home. The growing adoption of online pharmacies is also making it simpler for individuals to access their medications promptly and manage their treatment plans more effectively.

Regionally, the Europe migraine drugs industry size is projected to proliferate between 2024 and 2032, led by rising healthcare expenditure along with increased awareness and diagnosis of migraine disorders. Companies are investing in advanced treatments to support individuals experiencing migraines. Simultaneously, the heightened awareness and better diagnostic practices are leading to more accurate diagnoses and greater demand for effective migraine therapies in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360º synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence and prevalence of migraine
  - 3.2.1.2 Rising patient preference for non-invasive treatment
  - 3.2.1.3 Growing awareness and diagnosis of migraine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements
  - 3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Pricing analysis
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Pain relieving medication
- 5.2.1 Triptans
- 5.2.2 Analgesics
- 5.2.3 Ditans
- 5.2.4 Other pain-relieving medications
5.3 Prescription medication
- 5.3.1 Anticonvulsant
- 5.3.2 Antidepressant
- 5.3.3 Beta blocker
- 5.3.4 CGRP inhibitors
- 5.3.5 Other preventive medications

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Nasal
6.5 Transdermal

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Prescription drugs
7.3 OTC drugs

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug store & retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa